You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: OncoSynergy, Inc.            Topic: 999

    PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Secure Homomorphically Encrypted National Registry of COVID-19 Recovered Plasma Donors

    SBC: ELIMU INFORMATICS, INC.            Topic: 172

    PROJECT SUMMARY Treatment with convalescent plasma (CP) was recently approved by the FDA for seriously ill patients of COVID-19. There are many institutions and hospitals that have implemented CP programs, but they all face the challenge of finding sufficient and appropriate donors. The constraints of matching, imbalances in supply and demand, and privacy concerns pose several challenges to engage ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.

    SBC: Douleur Therapeutics Inc            Topic: NINDS

    Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Dynasore Analogues for Ocular Surface Protection

    SBC: MEDCHEM PARTNERS LLC            Topic: NEI

    7. PROJECT SUMMARY Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are initiated by loss of tear film homeostasis and can be ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS

    SBC: Novoron Bioscience Inc.            Topic: NINDS

    7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction

    SBC: ImmunoChem Therapeutics, LLC            Topic: 102

    PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants

    SBC: 149 Medical Inc.            Topic: 103

    PROJECT SUMMARY ABSTRACT Every year in the United States aboutof theinfants born extremely prematureandltweeks gestational age and andltg birth weightELGAdevelop intraventricular hemorrhageIVHIVH is associated with high risk for cerebral palsy and significant intellectual disabilitycausing lifelong implications for affected children and their families and considerable economic burdenIVH is caused ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government